North America's ALS Treatment Market: Propelling Global Growth by 42% through 2024-2028
The Amyotrophic Lateral Sclerosis (ALS) Treatment Market addresses the complexities of this condition and its diverse impacts within the healthcare landscape. ALS, a neurological disorder impacting the nervous system, has gained significant attention amid the COVID-19 pandemic, drawing focus on medical diagnoses, therapies, and innovative medications. With the global healthcare sector striving to understand the causes of diseases, ALS treatment stands as a critical segment, embracing health sciences, clinical trials, and neurological therapies.
Between 2023 and 2028, the size of the global market for ALS treatments is projected to increase by USD 663.7 million at a compound annual growth rate (CAGR) of 12.79%. Market navigates the challenges presented by neurological disorders, promoting advancements in medicine, healthcare management, and quality while exploring potential treatments such as Sodium Phenylbutyrate/Ursodoxicoltaurine and Edaravone.
Fastest growing topography of the Amyotrophic Lateral Sclerosis (ALS) Treatment Market
How Will North America's ALS Treatment Market Shape Global Growth?
In the upcoming period, North America is anticipated to contribute 42% to the global ALS treatment market expansion. Technavio's analysts meticulously delineate the regional patterns and influential factors shaping the market during this projection. The United States stands at the forefront of ALS treatment in North America, driven by leading pioneers such as Pfizer, Sangamo Therapeutics, and Celgene. These companies demonstrate strong commitments to marketing and raising patient awareness, exemplified by initiatives like Mitsubishi Tanabe Pharma America's 24-week Phase 3 study assessing the safety of oral Edaravone.
Notably, the ALS Association in the US annually boosts ALS awareness during May. Collaborations for innovative therapies are a prevailing trend, illustrated by Alector's partnership with GlaxoSmithKline and X-Chem's collaboration with Servier. The US is poised to dominate the North American market, supported by advanced healthcare infrastructure, accessible ALS therapies, and a high disease prevalence. Canada, expected to be the second-largest market, mirrors this growth trajectory due to the escalating prevalence of ALS. Discover how the ALS Treatment Market responds to multifaceted needs across diverse global scenarios in our best-selling report.
Amyotrophic Lateral Sclerosis Treatment Market: Key Highlights of the Report for 2024-2028